Kirby McInerney LLP is reminding investors of the upcoming May 28, 2024 deadline to seek lead plaintiff status in a federal securities class action related to bluebird bio, Inc. (NASDAQ: BLUE). The lawsuit concerns securities acquired during April 24, 2023, through December 8, 2023 (the “Class Period”).
During this period, Bluebird Bio announced FDA approval of its drug Lyfgenia (lovo-cel) for treating sickle cell disease in patients aged 12 and above with a history of vaso-occlusive events. However, the approval came with a black box warning after two patients developed AML during clinical trials. This information caused a significant drop in Bluebird Bio’s share price.
The lawsuit alleges that Bluebird Bio provided false and misleading information to investors, creating an inflated impression of its prospects. These alleged misrepresentations include claims regarding FDA approval, the acquisition of a priority review voucher, and the overstating of Lyfgenia’s clinical and commercial potential.
Investors who purchased Bluebird Bio securities during the Class Period and those with relevant information are encouraged to contact Thomas W. Elrod of Kirby McInerney LLP via email or through the provided contact form to discuss their rights or interests at no cost.
Kirby McInerney LLP specializes in securities, antitrust, whistleblower, and consumer litigation, having secured substantial recoveries for shareholders in securities litigation. Additional information about the firm is available on its website. This communication may be considered Attorney Advertising in certain jurisdictions.
